====== Abaloparatide for osteoporosis ======

{{rss>https://pubmed.ncbi.nlm.nih.gov/rss/search/16koWIt7v5kFs6pgpzTasAfY7VDwMCQXzU3M-8S1bkemq48cNJ/?limit=15&utm_campaign=pubmed-2&fc=20230424182510}}

see [[Osteoporosis treatment]].

(TymlosTM):

a [[recombinant DNA]] copy of the entire human [[parathyroid hormone]].

Rx: 80 micrograms SQ daily. Lifetime treatment limit of all parathyroid analogs total: 2 years

[[Abaloparatide]] increases [[bone formation]] for treating established [[osteoporosis]].

Initial treatment with abaloparatide may result in greater [[vertebral fracture]] reduction compared with [[alendronate]] in postmenopausal women with [[osteoporosis]]
((Leder BZ, Mitlak B, Hu MY, Hattersley G, Bockman RS. Effect of Abaloparatide
Versus Alendronate on Fracture Risk Reduction in Postmenopausal Women With
Osteoporosis. J Clin Endocrinol Metab. 2019 Nov 1. pii: dgz162. doi:
10.1210/clinem/dgz162. [Epub ahead of print] PubMed PMID: 31674644.
)).
----
Sequential therapy using ABL/[[alendronate]] (ALN) may be cost [[effective]] compared with generic ALN monotherapy in US men aged ≥ 50 years at high fracture risk, especially in those aged ≥ 60 years. Unbranded teriparatide (TPTD)/ALN and no treatment were dominated interventions (less QALY, more costs) compared with ABL/ALN or ALN monotherapy
((Hiligsmann M, Silverman SS, Singer AJ, Pearman L, Mathew J, Wang Y, Caminis J, Reginster JY. Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States. Pharmacoeconomics. 2023 Apr 22. doi: 10.1007/s40273-023-01270-x. Epub ahead of print. PMID: 37086385.))
----

Have not yet been studied in the chronic [[glucocorticoid]] population
((Taylor AD, Saag KG. Anabolics in the management of glucocorticoid-induced
osteoporosis: an evidence-based review of long-term safety, efficacy and place in
therapy. Core Evid. 2019 Aug 23;14:41-50. doi: 10.2147/CE.S172820. eCollection
2019. PubMed PMID: 31692480; PubMed Central PMCID: PMC6711555.)).